Stock listing

LSE:SCLP Scancell Holdings PLC Share Price

Home listing (LSE) of Scancell Holdings PLC

Follow Scancell Holdings PLC into a list and get an email when it puts out news.

Share price · LSE:SCLP

9.30p GBX (pence) -0.05 (-0.5%)

Close on Oct 16, 2026

Since Jul 6, 2026 -36.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
9.30p – 9.40p GBX (pence)Oct 16, 2026
Volume
278,709 sharesOct 16, 2026
Market value
£126.2M GBPAt the close on Oct 16, 2026 · price × 1.36B shares outstanding
Scancell Holdings PLC logo
Ticker
LSE:SCLP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Calls

Replays

  • Scancell Holdings (LSE:SCLP) — Clinical and Corporate Update

    Wed, Jun 25, 2025 · 6:00 AM ET

    Watch Transcript

Latest news

Issue of Equity, Director Dealing & Voting Rights

Oct 15, 2026

Preliminary Results

Oct 9, 2026

Notice of GM

Oct 2, 2026

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Sep 24, 2026

Scancell to Present at the H.C. Wainwright Sept 26

Sep 3, 2026

iSCIB1+ MHRA CTA Approval for Ph3 trial

Aug 19, 2026

Extension of Option Exercise Period

Jul 31, 2026

Correction: Merger and Financing

Jul 24, 2026

Merger and Financing

Jul 23, 2026

Scancell: Response to Press Speculation

Jun 26, 2026

All Scancell Holdings PLC news

Financings

  • Private placement of private placement (PIPE Financing)

    Oct 9, 2026

    Update: US$39.1M · US$0.1205 a share · Leerink Partners +2

    Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co.

    Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs)

    Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating

    Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones

    Announced Jul 23, 2026 · Update Jul 24, 2026 · Update Oct 9, 2026

  • Loan facility, partly convertible into Ordinary Shares, with warrants

    Oct 9, 2026

    Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each…

    Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility)

    Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+

    Announced Jul 23, 2026 · Update Jul 24, 2026 · Update Sep 24, 2026 · Update Oct 9, 2026

  • Private placement of new Ordinary Shares

    Jul 24, 2026

    Update: about US$12M · GBX 9 a share · Panmure Liberum Limited

    Dealers: Panmure Liberum Limited (lead)

    Announced Jul 23, 2026 · Update Jul 24, 2026

  • Ordinary Shares

    Jul 24, 2026

    Update: up to US$3M · GBX 9 a share

    Announced Jul 23, 2026 · Update Jul 24, 2026

Read by 6ix AI from the company's releases

Decks

Scancell Holdings PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 330 in all · newest Oct 15, 2026 · oldest 2008
Calls
1 call with a replay · 1 with a transcript · latest Jun 25, 2025
Decks
18 decks · latest August 2026

Where Scancell Holdings PLC is listed

ListingExchangeCountryCurrency
LSE:SCLP · Home listing · This pageLSEUnited KingdomGBX
OTC:SCNLFOTCUnited StatesUSD
AQUIS:SCLP.GBAQUISUnited KingdomGBX
Frankfurt:SCPFrankfurtGermanyEUR

Log in to ask 6ix AI your own questions about Scancell Holdings PLC.